Markets
markets

US court blocks Trump tariffs, but White House has workarounds, Goldman says

Stocks were green in premarket trading on Thursday, with the SPDR S&P 500 Trust up as much as 1.7% at one point after the US Court of International Trade struck down a major chunk of President Trump’s “Liberation Day” tariffs, ruling that the president misapplied the International Emergency Economic Powers Act for much of his sweeping package. 

But the court ruling may not change much in practice, given the White House’s multiple fallback options, according to a note published last night by economists at Goldman Sachs.

In a note led by Alec Phillips, Goldman’s economics research team estimated that the decision would block a 6.7 percentage point increase in the effective US tariff rate since early 2025 — including the 10% universal baseline tariff (worth 3.6 pp), a 20% hike on Chinese goods (2.7 pp), and a 25% tariff on imports from Canada and Mexico (0.4 pp) — and with it, nearly $200 billion in annual revenue.

However, Goldman expects the White House to “find other ways to impose tariffs,” likely by reimposing a temporary 15% tariff (under Section 122) and laying the groundwork for longer-term tariffs (under Section 301). Meanwhile, sectoral tariffs (those on steel, aluminum, and autos) remain in place and could expand under Section 232.

More Markets

See all Markets
(J. Edward Moreno/Sherwood News)

Novo and Lilly agree prices are falling — and disagree on what comes next

Novo Nordisk and Eli Lilly are cutting prices to reach more patients — with sharply different expectations about what that means for sales.

markets

Ozempic is no longer the most-searched for GLP-1 in the US

Ozempic, the popular diabetes drug made by Novo Nordisk, used to be short hand for an entire class of diabetes and weight-loss medications. Not anymore.

According to Google Trends data, as of January more people in the US are searching for Eli Lilly’s weight loss shot, Zepbound, than Ozempic. At the same time, interest in the word “Ozempic” now sits roughly on par with searches for “peptides," a catch-all term for a booming, loosely regulated category of experimental supplements.

The numbers hint at a cultural shift: Ozempic is no longer the only word people reach for when they think about weight-loss drugs. The market — and the vocabulary around it — is fragmenting.

This shift also reflected in sales numbers. For several quarters now, Lilly's diabetes and weight loss drugs have outsold Novo's and that gap is expected to widen this year.

markets

Crypto crumble smokes bitcoin-sensitive stocks and speculative tech

It’s a rough day out there, with the pain in the crypto markets being felt among select subgroups of US equities. Shortly before 2 p.m. ET on Wednesday here’s a snapshot of where some of the worst pinches are.

There is some overlap between some of these baskets, for instance bitcoin treasury company Strategy figures both in the “bitcoin sensitive” and “meme” basket. But in general it’s just a pretty ugly day for some of the more speculative corners of the stock market.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.